NASDAQ · Medical - Care Facilities

COMPASS Pathways plc (CMPS) Stock

$13.31 -0.60% NASDAQ: CMPS Healthcare

Valuation

Metric	Value
Price	$13.31
Market Cap	$1.28B
P/E Ratio	-6.19
P/B Ratio	4.48
P/S Ratio	0.00
EPS (TTM)	$0.00
52-Week High	$15.40
52-Week Low	$3.50
Dividend Yield	0.00%

Financials & Margins

Metric	Value
ROE	-150.89%
ROA	-33.62%
ROCE	-45.60%
Gross Margin	0.00%
Operating Margin	0.00%
Net Margin	0.00%
Debt/Equity	0.01
Current Ratio	3.32

Annual Financials (USD)

Metric	2021	2022	2023	2024	2025
Revenue	$0	$0	$0	$0	$0
Operating Profit	$-83.0M	$-110.0M	$-137.0M	$-178.0M	$-179.0M
Net Profit	$-72.0M	$-92.0M	$-118.0M	$-155.0M	$-288.0M
EPS	$-1.79	$-2.16	$-2.32	$-2.30	$-3.08
Op Margin	—	—	—	—	—

Balance Sheet (USD)

Metric	2021	2022	2023	2024	2025
Total Assets	$301.0M	$197.0M	$276.0M	$214.0M	$210.0M
Total Liabilities	$16.0M	$16.0M	$50.0M	$59.0M	$263.0M
Cash	$273.0M	$143.0M	$220.0M	$165.0M	$150.0M
Borrowings	$4.0M	$2.0M	$33.0M	$32.0M	$21.0M

Latest News

Johnson & Johnson’s Spravato sales growth supports psychedelic drug opportunity: Jefferies Proactive · Jul 15, 2026 Is COMPASS Pathways plc (CMPS) Stock a Psychedelic Medicine Opportunity After Positive COMP360 Data? Insider Monkey · Jul 15, 2026 The Race to Commercialize the World’s Most Powerful Psychedelic WSJ · Jul 14, 2026 Weekly Roundup on the Cannabis Sector & Psychedelic Sector Market Exclusive · Jul 13, 2026 Psychedelics guidance from the FDA set to benefit developers, including AtaiBeckley, Jefferies says Proactive · Jul 13, 2026

Cash Flow (USD)

Metric	2021	2022	2023	2024	2025
Operating Cash Flow	$-68.0M	$-105.0M	$-97.0M	$-119.0M	$-157.0M
Investing Cash Flow	$-1.0M	$-1.0M	$0	$0	$0
Financing Cash Flow	$2.0M	$1.0M	$-1.0M	$38.0M	$0
Net Cash Flow	$83.0M	$-130.0M	$77.0M	$-55.0M	$-15.0M
Free Cash Flow	$-68.0M	$-106.0M	$-97.0M	$-119.0M	$-157.0M

Valuation & Return Ratios

Metric	Value
PEG Ratio	0.16
EV / EBITDA	-4.62
FCF Yield	-12.47%
Quick Ratio	3.32
Interest Coverage	-35.54
Return 1Y	153.46%
Return 3Y	34.14%
Return 5Y	-61.99%

Ownership

Insiders Held7.83%

Institutions Held72.45%

Institutions Float Held78.60%

Institutional Holder	Shares	Report Date
Deep Track Capital, Lp	12,161,496	2026-03-31
RTW Investments LP	10,632,390	2026-03-31
Marshall Wace LLP	4,038,335	2026-03-31
Tang Capital Management, LLC	4,002,200	2026-03-31
BIT Capital GmbH	3,491,234	2026-03-31

Peer Comparison

Ticker	Price	Change	P/E	Market Cap	Div Yield
ACADACADIA Pharmaceuticals Inc.	$19.73	-2.86%	8.87	$3.40B	0.00%
DFTXDefinium Therapeutics, Inc.	$35.67	-0.92%	-10.87	$4.79B	0.00%
DNLIDenali Therapeutics Inc.	$18.41	-1.34%	-7.04	$2.94B	0.00%
GHRSGH Research PLC	$18.07	-2.32%	-22.71	$1.24B	0.00%
HRMYHarmony Biosciences Holdings, Inc.	$36.13	+0.28%	12.66	$2.10B	0.00%

About COMPASS Pathways plc

COMPASS Pathways plc is a mental healthcare company with a primary presence in the United Kingdom and the United States. Established in 2020 and headquartered in London, UK, the firm focuses on developing novel treatments. Its key product is COMP360, an investigational psilocybin therapy. This therapy has advanced through Phase IIb clinical trials for treatment-resistant depression and is currently undergoing Phase II trials for post-traumatic stress disorder. The company previously operated under the name COMPASS Rx Limited before rebranding to COMPASS Pathways plc in August 2020.

COMPASS Pathways plc is headquartered in GB.

COMPASS Pathways plc (CMPS) stock trades at $13.31 with a market capitalization of $1.28B. The stock is valued at a negative price-to-earnings (P/E) ratio of -6.19, reflecting a net loss over the last twelve months, price-to-book of 4.48, price-to-sales of 0.00. Over the past 52 weeks the stock has ranged between $3.50 and $15.40, and currently trades 13.6% below its 52-week high.

On profitability, COMPASS Pathways plc generates a return on equity (ROE) of -150.89% (negative, reflecting a net loss), return on capital employed of -45.60%.

Official website: compasspathways.com

COMPASS Pathways plc by the numbers, 2018–2025

Between 2018 and 2025 COMPASS Pathways plc reported revenue of $0 rising to $0. Compounded, revenue has grown —% a year over five years, —% over three, —% over the last twelve months. Net profit fell to $-288.0M.

On a trailing twelve-month basis to Mar '26, revenue is $0 and net profit $-179.0M.

Borrowings stand at $21.0M, cash on hand is $466.0M, cash from operations was $-157.0M in the latest year, positive in 0 of the last 8.

Return on equity has averaged 63.0% over five years, and was 543.4% in the most recent year.

The share price itself has compounded at -17.6% a year over five years, 13.6% over three, 273.9% over the last year. Past price movement is history, not a forecast.

Figures are as reported and in the company's own reporting currency. They describe what has already happened and carry no implication about what follows.

COMPASS Pathways plc (CMPS) — frequently asked questions

What is COMPASS Pathways plc (CMPS) stock price today?

COMPASS Pathways plc (CMPS) is currently trading at $13.31, down 0.6% today.

What is CMPS P/E ratio?

COMPASS Pathways plc's P/E ratio is -6.19. A negative P/E means the company reported a net loss over the last twelve months, so P/E is not a meaningful valuation measure for it right now.

What is CMPS return on equity (ROE)?

COMPASS Pathways plc's return on equity (ROE) is -150.89%. ROE measures net income relative to shareholders' equity. A negative ROE means the company reported a net loss over the period.

What is COMPASS Pathways plc's market cap?

COMPASS Pathways plc has a market capitalization of $1.28B.

Does CMPS pay a dividend?

COMPASS Pathways plc is not currently showing a dividend yield in our data, which means no recent cash dividend was recorded for it.

How much debt does CMPS carry?

COMPASS Pathways plc has a debt-to-equity ratio of 0.01. That compares total borrowings with shareholders' equity: a figure under 1 means equity exceeds debt.

What is CMPS's profit margin?

COMPASS Pathways plc reports a net profit margin of 0.00% — the share of revenue left after every cost, including tax and interest.

What sector is CMPS in?

COMPASS Pathways plc is classified under Healthcare, in the Medical - Care Facilities industry. Ratios are most informative compared with other companies in the same industry rather than across the whole market.

Which exchange is CMPS listed on?

COMPASS Pathways plc trades on NASDAQ under the ticker CMPS.

What is CMPS's 52-week range?

Over the last year COMPASS Pathways plc has traded between $3.50 and $15.40.

Related Healthcare Stocks

LLY Eli Lilly and Company $1273.46 -2.54% JNJ Johnson & Johnson $263.81 -1.42% ABBV AbbVie Inc. $285.64 +0.16% UNH UnitedHealth Group Incorporated Common Stock (DE) $418.09 -1.62% MRK Merck & Company, Inc. Common Stock (new) $145.27 -1.34% NVS Novartis AG $151.12 -3.30% AZN AstraZeneca PLC $171.49 -0.63% TMO Thermo Fisher Scientific Inc $673.82 -0.40% AMGN Amgen Inc. $439.26 -1.79% GILD Gilead Sciences, Inc. $156.04 -0.73% ABT Abbott Laboratories $103.70 +1.16% NVO Novo Nordisk A/S $39.05 -0.96%

Screens CMPS currently matches

On the figures above, COMPASS Pathways plc passes the filters for 8 of our ready-made screens, among them Low Debt Stocks, Small Cap Stocks, Debt Free Stocks Under $100. Appearing on a screen means the numbers meet its filters today and nothing more; the list is rebuilt whenever the data changes.

Low Debt Stocks Small Cap Stocks Debt Free Stocks Under $100 Debt Free Stocks Stocks Under $100 Stocks Under $50 Debt to Equity Below 1 Stocks High Current Ratio Stocks

Related stock screens

High ROE Healthcare Stocks Low P/E Healthcare Stocks High Net Margin Healthcare Stocks Dividend Healthcare Stocks Low Debt Healthcare Stocks High ROE Stocks Low P/E Stocks High Net Margin Stocks Dividend Stocks Low Debt Stocks Nasdaq High ROE Stocks All stock screens

Run Stock Screener Investing Guides

Data for information only, not investment advice. Figures may be delayed or inaccurate; verify against company filings. See our disclaimer.